Tagged with

logistics The founder of Bomi Group’s affiliate in Argentina discusses the accomplishments of his firm thus far, and the challenges they have faced while trying to enter the very consolidated Argentinian logistics market. What was your first exposure to the healthcare logistics business? My background is in biochemistry and I worked…

orphan drugs Aegerion’s representative in Argentina discusses her efforts to raise awareness of Homozygous Familial Hypercholesteremia (HoFH), the rare disease targeted by her company’s ultra-orphan drug, and the remaining challenges of diagnosing patients. What is the current state of affairs for HoFH patients in Argentina? So far, as lomitapide is not yet…

pricing Daniel Varde, Deloitte’s top consultant for the healthcare and life sciences sector in Latin America, discusses the interaction of global, Latin American, and Argentinian healthcare trends, and strategic techniques for optimizing a pharmaceutical firm’s performance in Argentina’s price-controlled, high inflation market. With the current inflationary pressures to reduce costs, why…

innovation Lee Han-Koo, president of Daehwa Pharmaceutical, explains his strategy to corner the transdermal drug delivery system (TDDS) market through innovative patch products as well as a special focus on oral anticancer medication. Could you briefly introduce our readers to Daehwa? Daehwa was founded in January 1984 and listed on the…

healthcare “Argentina’s health system is in agony” In March 2002, amidst an economic crisis and national healthcare emergency the then Minister of Health Gines Gonzales Garcia declared “Argentina’s health system is in agony… What is lacking is money, not drugs. Our country has the best pharmaceutical industry in Latin America. The…

diabetes treatment Novo Nordisk’s market access and public affairs director discusses the state of diabetes management in Mexico, highlighting the government’s recent commitment to tackle this public health issue and the company’s contribution to the dialogue. You were appointed as the director for public affairs two years ago, and recently of market…

regulatory Alejandro Luna and José Alfredo Sedano, lawyers at the leading legal firm of Santamarina y Steta, discuss the current legal challenges faced by companies in the pharmaceutical and healthcare sector in Mexico and urge for the amendment of the current regulatory framework. How was the healthcare and life science practice…

biotech The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020 and explains how Mexico and the rest of the region will contribute to this achievement. You were appointed head of…

oncology In the Mexican pharmaceutical industry change is the name of the game. The general director of Pierre Fabre Mexico and Central America expands on how the company has adapted its go-to-market strategy and has succeeded in positioning itself as a top player in women’s health and primary care, lead by…

clinical research The general director of the National Institute for Psychiatry discusses the Institute’s commitment to translating clinical research into better care for patients, the social stigma patients with mental disorders still face in Mexico and the increasing importance of mental health on productivity and the country’s economic development. You have been…

R&D James Jun, CEO of KT&G Life Sciences, discusses his company’s new entry into the Korean pharma market and the role that the KT&G brand can play in accelerating its drug development process. How did KT&G Life Sciences begin, and what was the reasoning behind starting this company in the first…

innovation Korean success story Boryung has a goal to become the number one domestic pharmaceutical company in the coming years. The company’s CEO, Choi Tae-Hong, discusses this strategy and the victory that their antihypertensive product Kanarb has brought in the Korean innovation game. You had a lengthy career at Janssen prior…